Citi analyst David Lebowitz downgraded Pliant Therapeutics (NASDAQ: PLRX) from Buy to Neutral with a price target of $4.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE